Short Interest in VolitionRX Limited (NYSEAMERICAN:VNRX) Grows By 24.4%

VolitionRX Limited (NYSEAMERICAN:VNRX) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 676,713 shares, a growth of 24.4% from the December 15th total of 543,884 shares. Currently, 0.6% of the company’s shares are sold short. Based on an average trading volume of 2,688,706 shares, the days-to-cover ratio is currently 0.3 days. Based on an average trading volume of 2,688,706 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.6% of the company’s shares are sold short.

VolitionRX Stock Performance

Shares of NYSEAMERICAN:VNRX traded up $0.05 during trading on Tuesday, reaching $0.34. 2,976,676 shares of the stock were exchanged, compared to its average volume of 2,362,411. The firm’s 50-day moving average price is $0.30 and its 200 day moving average price is $0.50. The firm has a market cap of $42.23 million, a price-to-earnings ratio of -1.50 and a beta of 1.23. VolitionRX has a 12-month low of $0.22 and a 12-month high of $0.94.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.